{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Superantigènes : Questions médicales les plus fréquentes",
"headline": "Superantigènes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Superantigènes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-25",
"dateModified": "2025-03-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Superantigènes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antigènes",
"url": "https://questionsmedicales.fr/mesh/D000941",
"about": {
"@type": "MedicalCondition",
"name": "Antigènes",
"code": {
"@type": "MedicalCode",
"code": "D000941",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.050"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Antigènes mineurs de stimulation lymphocytaire",
"alternateName": "Minor Lymphocyte Stimulatory Antigens",
"url": "https://questionsmedicales.fr/mesh/D016747",
"about": {
"@type": "MedicalCondition",
"name": "Antigènes mineurs de stimulation lymphocytaire",
"code": {
"@type": "MedicalCode",
"code": "D016747",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.050.820.625"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Superantigènes",
"alternateName": "Superantigens",
"code": {
"@type": "MedicalCode",
"code": "D018089",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mary Hongying Cheng",
"url": "https://questionsmedicales.fr/author/Mary%20Hongying%20Cheng",
"affiliation": {
"@type": "Organization",
"name": "Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261."
}
},
{
"@type": "Person",
"name": "Rebecca A Porritt",
"url": "https://questionsmedicales.fr/author/Rebecca%20A%20Porritt",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, Cedars-Sinai Medical Center, Los Angeles, CA 90048."
}
},
{
"@type": "Person",
"name": "Moshe Arditi",
"url": "https://questionsmedicales.fr/author/Moshe%20Arditi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, Cedars-Sinai Medical Center, Los Angeles, CA 90048."
}
},
{
"@type": "Person",
"name": "Ivet Bahar",
"url": "https://questionsmedicales.fr/author/Ivet%20Bahar",
"affiliation": {
"@type": "Organization",
"name": "Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261."
}
},
{
"@type": "Person",
"name": "Samuel Ken-En Gan",
"url": "https://questionsmedicales.fr/author/Samuel%20Ken-En%20Gan",
"affiliation": {
"@type": "Organization",
"name": "Antibody & Product Development Lab, Experimental Drug Development Centre - Bioinformatics Institute (EDDC-BII), Agency for Science Technology and Research (ASTAR), Singapore, Singapore."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Evaluating the effectiveness of stromal-vascular fraction (SVF) cells along with subcision method in the treatment of acne scars: A double-blind randomized controlled clinical trial study.",
"datePublished": "2022-09-26",
"url": "https://questionsmedicales.fr/article/36086927",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jocd.15375"
}
},
{
"@type": "ScholarlyArticle",
"name": "ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol.",
"datePublished": "2022-12-20",
"url": "https://questionsmedicales.fr/article/36600424",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjopen-2022-067251"
}
},
{
"@type": "ScholarlyArticle",
"name": "Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.",
"datePublished": "2022-05-23",
"url": "https://questionsmedicales.fr/article/35617986",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/S2213-2600(22)00088-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison Between Esketamine and Alfentanil for Hysteroscopy: A Prospective, Double-Blind, Randomized Controlled Trial.",
"datePublished": "2024-08-14",
"url": "https://questionsmedicales.fr/article/39161682",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2147/DDDT.S472651"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy of Liposomal Melatonin in sleep EEG in Childhood: A Double Blind Case Control Study.",
"datePublished": "2022-12-29",
"url": "https://questionsmedicales.fr/article/36612875",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph20010552"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Antigènes",
"item": "https://questionsmedicales.fr/mesh/D000941"
},
{
"@type": "ListItem",
"position": 4,
"name": "Superantigènes",
"item": "https://questionsmedicales.fr/mesh/D018089"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Superantigènes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Superantigènes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Superantigènes",
"description": "Comment diagnostique-t-on une infection par superantigènes ?\nQuels tests sont utilisés pour détecter les superantigènes ?\nLes symptômes aident-ils au diagnostic des superantigènes ?\nPeut-on identifier des superantigènes par PCR ?\nLes tests d'allergie sont-ils utiles pour les superantigènes ?",
"url": "https://questionsmedicales.fr/mesh/D018089?mesh_terms=Double-Blind+Method&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Superantigènes",
"description": "Quels sont les symptômes d'une intoxication par superantigènes ?\nLes superantigènes provoquent-ils des douleurs ?\nY a-t-il des symptômes neurologiques associés ?\nLes symptômes varient-ils selon le type de superantigène ?\nLes symptômes sont-ils immédiats après exposition ?",
"url": "https://questionsmedicales.fr/mesh/D018089?mesh_terms=Double-Blind+Method&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Superantigènes",
"description": "Comment prévenir les infections par superantigènes ?\nLes vaccins peuvent-ils prévenir les infections par superantigènes ?\nFaut-il éviter certains aliments pour prévenir les superantigènes ?\nLes mesures d'hygiène sont-elles suffisantes ?\nLes superantigènes peuvent-ils être évités en milieu hospitalier ?",
"url": "https://questionsmedicales.fr/mesh/D018089?mesh_terms=Double-Blind+Method&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Superantigènes",
"description": "Quel est le traitement principal pour les infections par superantigènes ?\nLes corticostéroïdes sont-ils efficaces contre les superantigènes ?\nFaut-il hospitaliser les patients atteints de superantigènes ?\nLes traitements symptomatiques sont-ils recommandés ?\nY a-t-il des traitements spécifiques pour les superantigènes ?",
"url": "https://questionsmedicales.fr/mesh/D018089?mesh_terms=Double-Blind+Method&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Superantigènes",
"description": "Quelles sont les complications possibles des infections par superantigènes ?\nLes superantigènes peuvent-ils causer des lésions organiques ?\nY a-t-il un risque de récidive après une infection par superantigènes ?\nLes complications sont-elles plus fréquentes chez certains patients ?\nLes complications peuvent-elles survenir rapidement ?",
"url": "https://questionsmedicales.fr/mesh/D018089?mesh_terms=Double-Blind+Method&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Superantigènes",
"description": "Quels sont les principaux facteurs de risque pour les infections par superantigènes ?\nLes enfants sont-ils plus à risque d'infections par superantigènes ?\nLes personnes âgées sont-elles à risque accru ?\nLes antécédents d'infections augmentent-ils le risque ?\nLes conditions de vie peuvent-elles influencer le risque ?",
"url": "https://questionsmedicales.fr/mesh/D018089?mesh_terms=Double-Blind+Method&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on une infection par superantigènes ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sérologiques et l'identification des toxines."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les superantigènes ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests ELISA et des cultures bactériennes peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les symptômes aident-ils au diagnostic des superantigènes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes cliniques orientent le diagnostic, mais ne sont pas spécifiques."
}
},
{
"@type": "Question",
"name": "Peut-on identifier des superantigènes par PCR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la PCR peut détecter les gènes codant pour les superantigènes."
}
},
{
"@type": "Question",
"name": "Les tests d'allergie sont-ils utiles pour les superantigènes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les tests d'allergie ne sont pas pertinents pour les superantigènes."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une intoxication par superantigènes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fièvre, éruption cutanée, et choc toxique."
}
},
{
"@type": "Question",
"name": "Les superantigènes provoquent-ils des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires et articulaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes neurologiques comme des maux de tête peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de superantigène ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon la souche bactérienne impliquée."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils immédiats après exposition ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent apparaître rapidement, souvent dans les 24 heures."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections par superantigènes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par une bonne hygiène et des pratiques alimentaires sûres."
}
},
{
"@type": "Question",
"name": "Les vaccins peuvent-ils prévenir les infections par superantigènes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques contre les superantigènes."
}
},
{
"@type": "Question",
"name": "Faut-il éviter certains aliments pour prévenir les superantigènes ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter les aliments mal cuits ou contaminés peut réduire le risque."
}
},
{
"@type": "Question",
"name": "Les mesures d'hygiène sont-elles suffisantes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont essentielles, mais doivent être combinées avec d'autres pratiques préventives."
}
},
{
"@type": "Question",
"name": "Les superantigènes peuvent-ils être évités en milieu hospitalier ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des protocoles stricts d'hygiène et de désinfection aident à prévenir leur propagation."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal pour les infections par superantigènes ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est l'administration d'antibiotiques appropriés."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces contre les superantigènes ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les corticostéroïdes peuvent réduire l'inflammation mais ne traitent pas l'infection."
}
},
{
"@type": "Question",
"name": "Faut-il hospitaliser les patients atteints de superantigènes ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hospitalisation peut être nécessaire en cas de choc toxique sévère."
}
},
{
"@type": "Question",
"name": "Les traitements symptomatiques sont-ils recommandés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements symptomatiques comme des antipyrétiques peuvent être utiles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour les superantigènes ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitement spécifique ciblant les superantigènes."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des infections par superantigènes ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent le choc toxique, la défaillance multiviscérale et la septicémie."
}
},
{
"@type": "Question",
"name": "Les superantigènes peuvent-ils causer des lésions organiques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent entraîner des lésions aux reins, au foie et aux poumons."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de récidive après une infection par superantigènes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections peuvent récidiver, surtout si les facteurs de risque persistent."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles plus fréquentes chez certains patients ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients immunodéprimés sont plus à risque de complications graves."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles survenir rapidement ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent se développer rapidement après l'infection."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour les infections par superantigènes ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'immunodépression, les interventions chirurgicales et l'hygiène insuffisante."
}
},
{
"@type": "Question",
"name": "Les enfants sont-ils plus à risque d'infections par superantigènes ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants peuvent être plus vulnérables en raison de leur système immunitaire immature."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles à risque accru ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées ont un risque accru en raison de la diminution de l'immunité."
}
},
{
"@type": "Question",
"name": "Les antécédents d'infections augmentent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents d'infections peuvent prédisposer à de nouvelles infections."
}
},
{
"@type": "Question",
"name": "Les conditions de vie peuvent-elles influencer le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conditions de vie insalubres augmentent le risque d'infections par superantigènes."
}
}
]
}
]
}
Subcision method is one of the main techniques for treatment of acne scars or stromal-vascular fraction (SVF) and combined therapy can improve treatment strategy....
To use subcision method along with SVF for treatment of acne scar and comprised with alone subcision method....
In this double-blind clinical trial study, 10 patients with acne scars were entered into the study. Subcision technique was randomly performed on one side of the face and subcision technique plus SVF ...
In terms of volume and area of scars, the mean percent change was 46.55 ± 13.92 and 44.60 ± 5.76, for the case group, and 13.31 ± 9.27 and 11.28 ± 9.64 for the control group, respectively. So, combine...
According to the acquired results, combined therapy can be considered as effective and safe treatment for acne scars with significant higher efficacy compared with subcision alone....
Sepsis is a major cause of death among hospitalised patients. Accumulating evidence suggests that immune response during sepsis cascade lies within a spectrum of dysregulated host responses. On the on...
ImmunoSep is a randomised placebo-controlled phase 2 clinical trial with a double-dummy design in which the effect of precision immunotherapy on sepsis phenotypes with MALS and immunoparalysis is stud...
The protocol is approved by the German Federal Institute for Drugs and Medical Devices; the National Ethics Committee of Greece and by the National Organization for Medicines of Greece; the Central Co...
NCT04990232....
Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone p...
In this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites), Singapore (two sites), a...
Between Dec 1, 2020, and April 13, 2021, 1047 patients were assessed for eligibility. 1010 patients were enrolled and randomly assigned, 516 (51%) to baricitinib plus remdesivir plus placebo and 494 (...
In hospitalised patients with COVID-19 requiring supplemental oxygen by low-flow, high-flow, or non-invasive ventilation, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in simi...
National Institute of Allergy and Infectious Diseases....
This study aimed to establish the 95% effective dose (ED95) of esketamine in combination with propofol for hysteroscopy and then to evaluate its efficacy and safety profile....
This prospective, double-blind, randomized controlled trial consisted of two cohorts. In cohort 1, 45 women aged 18-65 years undergoing hysteroscopy were randomly assigned to either group E (esketamin...
The ED95 of esketamine was 0.254 mg/kg (95% CI: 0.214-1.004), while that of alfentanil was 9.121 μg/kg (95% CI: 8.479-13.364). The anesthesia success rate was 93.0% in group E and 95.2% in group A (p ...
This study determined the ED 95 dose of esketamine for intravenous general anesthesia during hysteroscopy. Esketamine showed less respiratory and hemodynamic depression, as well as fewer adverse effec...
www.chictr.org.cn, (ChiCTR2300077283); registered November 3, 2023....
Electroencephalography (EEG) is pivotal in the clinical assessment of epilepsy, and sleep is known to improve the diagnostic yield of its recording. Sleep-EEG recording is generally reached by either ...
Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease that may advance to fibrosis and lead to mortality; however, no pharmacotherapy is currently available. We tested the hypothesis t...
To determine whether intravenous vitamin C compared with placebo, reduces vasopressor requirements in patients with vasoplegic shock....
Double-blinded, randomised clinical trial (RCT) conducted in two intensive care units in Perth, Australia. Vasopressor requirements at enrolment needed to be >10 μg/min noradrenaline after hypovolaemi...
Of the 71 patients randomised (35 vitamin C, 36 placebo group), the median vasopressor duration was 44 h [95% CI, 37-54 h] and 55 h [95% CI, 33-66 h]) in the vitamin C and placebo groups (p = 0.057). ...
In this RCT of patients with vasoplegic shock of at least moderate severity, the use of IV vitamin C compared with placebo did not significantly reduce the duration of vasopressors....
Prospective registration - trial number ACTRN12617001392358....
Fibrotic hypersensitivity pneumonitis (FHP) is an irreversible lung disease with high morbidity and mortality. We sought to evaluate the safety and effect of pirfenidone on disease progression in such...
We conducted a single-centre, randomised, double-blinded, placebo-controlled trial in adults with FHP and disease progression. Patients were assigned in a 2:1 ratio to receive either oral pirfenidone ...
After randomising 40 patients, enrolment was interrupted by the COVID-19 pandemic. There was no significant between-group difference in FVC% at week 52 (mean difference -0.76%, 95% CI -6.34 to 4.82). ...
The trial was underpowered to detect a difference in the primary end point. Pirfenidone was found to be safe and improved PFS in patients with FHP....
NCT02958917....
Pain after soft tissue injuries in and around the ankle is a troublesome process in terms of patient comfort and mobilization. The aim of this study was to compare the analgesic efficacy of intravenou...
We conducted a prospective, double-blind, randomized controlled study in a tertiary hospital. The patients were divided into two groups as those administered IV 400 mg ibuprofen and IV 20 mg tenoxicam...
One hundred and twenty-four patients were included in the study. There were 62 patients in the tenoxicam group and 62 patients in the ibuprofen group. When VAS scores were compared, it was found that ...
